As Beijing’s pilot reform spreads nationwide to cut prices of drugs and improve their efficacy and safety, companies are under mounting pressure to invest in innovative drugs development and reduce reliance on low profit products that are the same copies of original drugs.
New policy environment demanding cheaper drugs adds pressure to innovate.
Engineers at Sandia National Laboratories have improved their SpinDx mobile diagnostic device so that it can perform both protein and nucleic acid tests. This lets it identify nearly any cause of illness in human patients, including viruses, bacteria, toxins, and immune system markers of chemical agent exposure.
This mobile diagnostic machine can test for viruses, bacteria, and active toxins.
New research from MIT has resulted in a microfluidic device, the tumor analysis platform (TAP), that can simulate different cancer treatments on biopsied tumor tissue. The TAP device can be 3D printed within one hour and is slightly larger than a quarter. Three cylindrical shafts rise from the surface of the device and serve as ports to input and drain fluids, as well as remove air bubbles. Fluid—including various media, fluorescent markers, or lymphocytes—gets injected into an inlet port adjacent to the trap. The fluid enters through the inlet port and flows past the trap.
A new 3D-printed device from MIT researchers allows for the testing of different cancer treatments on live tumor tissue outside the human body.
More effective treatments for Multiple Sclerosis on the horizon?
Dr. Metcalfe and her company are already looking to take down other severe diseases as well.
“Psoriasis is high up on our list, and diabetes is another. Downstream there are all the dementias because a LIF is a major health factor for the brain. So if we can get it into the brain we can start protecting against dementia.”
Please SHARE this with your friends and family.
Research in immunotherapy identifies mechanism that helps fight lung cancer and melanoma.
In a breakthrough discovery, scientists from Harvard Medical School along with a team at Bar-Ilan University have uncovered a mechanism in which the immune system is capable of attacking cancer cells. This contributes greatly to research in immunotherapy, particularly in fighting lung cancer and melanoma (skin cancer). The research team was composed of Prof. Nick Hainin of Harvard Medical School and Prof. Erez Levanon of the Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University, along with doctoral student, Ilana Buchumansky and many others.
The study was published two weeks ago in the journal Nature, detailing how scientists have uncovered a mechanism that assists the cell by leaving markers on human virus-like genes thereby preventing them from being recognized as viruses. When this channel is inhibited, the immune system can be utilized to destroy cancerous cells, particularly in the cases of lung cancer and melanoma. The immune system reacts when this path is blocked or shut off, and allows the body to destroy cancer cells at a more effective rate.
Salk researchers have mapped the genomes and epigenomes of genetically modified plant lines with the highest resolution ever to reveal exactly what happens at a molecular level when a piece of foreign DNA is inserted. Their findings, published in the journal PLOS Genetics on January 15, 2019, elucidate the routine methods used to modify plants, and offer new ways to more effectively minimize potential off-target effects.
The study, published Friday in JAMA Network Open, looked county by county across the United States between 2013 and 2015. It found that where pharmaceutical companies spent more on meals, travel and speaking fees for doctors, there were more opioid prescriptions — and more fatal overdoses.
Question To what extent is pharmaceutical industry marketing of opioids to physicians associated with subsequent mortality from prescription opioid overdoses?
Findings In this population-based, cross-sectional study, $39.7 million in opioid marketing was targeted to 67 507 physicians across 2208 US counties between August 1, 2013, and December 31, 2015. Increased county-level opioid marketing was associated with elevated overdose mortality 1 year later, an association mediated by opioid prescribing rates; per capita, the number of marketing interactions with physicians demonstrated a stronger association with mortality than the dollar value of marketing.
Meaning The potential role of pharmaceutical industry marketing in contributing to opioid prescribing and mortality from overdoses merits ongoing examination.
